Evidence map›Paper›PMID 40349132›Full record

ArticleThe oncologist2025

Palliative and end-of-life care in Asian and White patients with metastatic lung cancer.

Xiao Hu, John W Melson, Stacey S Pan, Yana V Salei, Lori Pai, Susan K Parsons, Yu Cao

Abstract read
In one paragraph

Article in The oncologist, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xiao HuDivision of Hematology-Oncology, Department of Medicine, Tufts Medical Center, Boston, MA, United States.ORCID 0000-0001-9036-8455
John W MelsonDivision of Hematology, Oncology and Palliative Care, Department of Medicine, Virginia Commonwealth University, Richmond, VA, United States.
Stacey S PanDivision of Hematology-Oncology, Department of Medicine, Tufts Medical Center, Boston, MA, United States.
Yana V SaleiDepartment of Medicine, Tufts Medical Center, Boston, MA, United States.
Lori PaiDivision of Hematology-Oncology, Department of Medicine, Tufts Medical Center, Boston, MA, United States.
Susan K ParsonsDivision of Hematology-Oncology, Department of Medicine, Tufts Medical Center, Boston, MA, United States.ORCID 0000-0003-0282-6490
Yu CaoDivision of Hematology-Oncology, Department of Medicine, Tufts Medical Center, Boston, MA, United States.ORCID 0000-0002-5661-5851

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundData on palliative and end-of-life care for Asian patients with metastatic lung cancer in the United States are limited, though this is the leading cause of cancer death in this group. Early palliative care improved quality of life and survival in patients with metastatic lung cancer treated with chemotherapy. We examined palliative and end-of-life care patterns in Asian and White patients with metastatic lung cancer in the era of novel therapy.

methodsPatients newly diagnosed with metastatic lung cancer from 2014 to 2019 were identified at our institution. Patient and disease characteristics and treatment information were compared between Asian and White patients by Mann-Whitney U test and Chi-square tests. Time-to-palliative care involvement was compared via log-rank test.

resultsBoth Asian (N = 89) and White (N = 197) patients had low rates of palliative care involvement (38.2% vs 37.6%), with median time from diagnosis to first encounter exceeding a year. The most given frontline systemic therapy was targeted therapy and chemotherapy in Asian and White patients, respectively. Of 22 Asian (24.7%) and 74 White (37.6%) patients who died, Asian patients more often died in-hospital (68.2% vs 32.4%, P = .004), and did not have documented code status discussions with their outpatient oncologists (0% vs 24.3%, P = .010) within 6 months preceding death.

conclusionEarly palliative care appears challenging to implement for Asian and White patients newly diagnosed with metastatic lung cancer in a real-world setting. A more patient-centered approach to integrating palliative and end-of-life care communications and interventions alongside precision oncology warrants further study.

Indexed as

Lung NeoplasmsPalliative CareTerminal CareAdultAgedAged, 80 and overAsianFemaleHumansMaleMiddle AgedNeoplasm MetastasisQuality of LifeWhiteadvance care discussionAsianend-of-life carehospicelung cancerPalliative care

Identifiers

PMID40349132
PMCPMC12065943

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.